NCT05138510

Brief Summary

In the present study, we propose a mixed methods approach to characterize and address the sexual health needs among women with breast cancer at the time of diagnosis and throughout treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
93

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2020

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

October 26, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 1, 2021

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 23, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 23, 2025

Completed
Last Updated

January 28, 2026

Status Verified

January 1, 2026

Enrollment Period

4.9 years

First QC Date

October 26, 2021

Last Update Submit

January 27, 2026

Conditions

Outcome Measures

Primary Outcomes (4)

  • Determine changes in sexual well-being for women with breast cancer

    Determine changes in sexual well-being throughout the course of breast cancer treatment, pre- and post-implementation of developed educational materials using the Sexual Health Among Women Receiving Breast Cancer Treatment Survey

    1 year

  • Determine educational resources currently used for sexual health information

    Determine patients' self reported list of educational media received regarding sexual health during breast cancer treatment using the PROM survey (BREAST-Q)

    1 year

  • Determine educational resources currently used for sexual health information

    Determine patients' self reported list of educational media received regarding sexual health during breast cancer treatment using the Sexual Health Among Women Receiving Breast Cancer Treatment Survey

    1 year

  • Determine patients preferred type of education for sexual health

    Determine the patients preferred type and timing of educational interventions for sexual health using the Sexual Health Among Women Receiving Breast Cancer Treatment Survey

    1 year

Study Arms (5)

Stage 0

Ductal carcinoma in situ. Timing: start of endocrine therapy

Behavioral: Focus Group

Stages I-III Surgery first

Invasive cancer. Surgery first Timing: start of endocrine therapy

Behavioral: Focus Group

Stages I-III, neoadjuvant chemotherapy first

Invasive cancer. Neoadjuvant chemotherapy first Timing: during neoadjuvant chemotherapy

Behavioral: Focus Group

Stage IV

Metastatic cancer, chemotherapy only, no invasive surgery Timing: 2 months into treatment

Behavioral: Focus Group

Survivors

Timing: any time

Behavioral: Focus Group

Interventions

Focus GroupBEHAVIORAL

Providers with extensive training and expertise in the subject will lead the virtual focus groups over Zoom using a semi-structured guide. Topics will focus on education received from the health care team, information received from outside sources, and patient recommendations on the type and timing of information preferred. We will create an analytic report based on the focus group findings, which will be used to inform the development of educational material. Sexual well-being is currently measured longitudinally on a 0-100 point scale as a component of a validated patient-reported outcome measures (PROM) survey (BREAST-Q) distributed to all breast cancer patients. These scores will be analyzed in patients with and without educational interventions for comparison.

Stage 0Stage IVStages I-III Surgery firstStages I-III, neoadjuvant chemotherapy firstSurvivors

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients diagnosed with ductal carcinoma in situ or invasive breast cancer, seen in the breast center between 9/1/2019 to present, will potentially be recruited to participate. Patients less than 18 years of age and those with non-cancer diagnoses or prior history of breast cancer will be excluded.

You may qualify if:

  • Patients diagnosed with ductal carcinoma in situ or invasive breast cancer, seen in the breast center between 09/01/2019 to present, will potentially be recruited to participate.

You may not qualify if:

  • Patients less than 18 years of age and those with non-cancer diagnoses or prior history of breast cancer will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado Hospital

Aurora, Colorado, 80045, United States

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Focus Groups

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Data CollectionEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Sarah Tevis

    Colorado Research Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2021

First Posted

December 1, 2021

Study Start

December 1, 2020

Primary Completion

October 23, 2025

Study Completion

October 23, 2025

Last Updated

January 28, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Individual Participant Data will not be shared with other researchers. Individual Participant Data will be housed in a deidentified format in the secure, encrypted REDCap database of the University of Colorado School od Medicine.

Locations